ArticleFrontiers in immunology2023

T-cells engineered with a novel VHH-based chimeric antigen receptor against CD19 exhibit comparable tumoricidal efficacy to their FMC63-based counterparts.

Fatemeh Nasiri et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.